The rise of compounded semaglutide as an accessible alternative to brand-name GLP-1 medications has been one of the more consequential developments in the US weight loss treatment market over the past several years. As demand for semaglutide surged following its FDA approval for chronic weight management, widespread shortages of the branded products Ozempic and Wegovy created conditions under which compounded versions — produced by licensed pharmacies — became widely available through telehealth platforms. Understanding the regulatory framework, the current legal landscape, and the distinctions between compounded and brand-name products is essential for individuals evaluating their options.
What Is Compounded Semaglutide?
Drug compounding is the process by which a licensed pharmacist prepares a customized medication for an individual patient based on a valid prescription from a licensed prescriber. Compounded drugs are not FDA-approved products — they are not evaluated by the FDA for safety, efficacy, or manufacturing quality in the same way that commercially manufactured drugs are. However, compounding is a longstanding and legally sanctioned pharmaceutical practice in the United States, governed by provisions of the Federal Food, Drug, and Cosmetic Act and overseen by state boards of pharmacy.
Compounded semaglutide typically refers to semaglutide active pharmaceutical ingredient (API) prepared by a licensed pharmacy for subcutaneous injection, often formulated at doses that mirror the titration schedules of brand-name products such as Wegovy. The compounded product may also include inactive ingredients, such as vitamin B12, that differ from the branded formulation.
The Shortage Period and FDA Permissions
Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, pharmacies may compound copies of commercially available drugs when those drugs appear on the FDA’s drug shortage list. Semaglutide injection products — specifically Ozempic and Wegovy — were placed on the FDA’s shortage list beginning in 2022 and remained there through early 2025, reflecting an extended period during which demand substantially exceeded manufacturing capacity.
During this period, both 503A compounding pharmacies (traditional patient-specific compounders) and 503B outsourcing facilities (larger-scale compounders) were legally permitted to compound semaglutide under the shortage exemption. This regulatory opening enabled dozens of telehealth platforms to offer compounded semaglutide programs at significantly lower price points than the branded alternatives, which carried list prices exceeding $1,000 per month before insurance.
The End of the Shortage and Its Regulatory Implications
On February 21, 2025, the FDA determined that the shortage of semaglutide injection products had been resolved, removing the drugs from the official shortage list. This determination had materially different implications for different categories of compounders.
For 503B outsourcing facilities — which produce semaglutide in bulk for distribution — the FDA’s position was that compounding must cease once the shortage designation ended. A compliance deadline of May 22, 2025 was established for 503B facilities to wind down semaglutide compounding operations, beyond which continued large-scale production would be subject to regulatory action.
For 503A pharmacies — which compound medications for individual patients based on specific prescriptions — operations have continued under the traditional patient-specific compounding framework. 503A pharmacies operate under state licensing authority and are permitted to compound copies of commercially available drugs under certain conditions, though the extent and enforceability of these permissions in the post-shortage environment has been the subject of ongoing legal and regulatory discussion.
FDA Enforcement Activity
In September 2025, the FDA issued more than 55 warning letters to online sellers of compounded GLP-1 medications, citing misleading direct-to-consumer advertising and marketing practices. The enforcement action targeted platforms making efficacy claims and promotional representations that the FDA determined were inconsistent with permissible compounded drug marketing. The letters did not broadly prohibit compounding itself but targeted specific advertising conduct.
Compounded vs. Brand-Name Semaglutide: Key Distinctions
Several important distinctions exist between compounded semaglutide and brand-name products such as Wegovy that individuals should understand before making any decisions:
FDA Approval Status
Wegovy and Ozempic are FDA-approved medications that have undergone the full regulatory review process for safety, efficacy, manufacturing standards, and labeling. Compounded semaglutide is not FDA-approved and has not undergone this evaluation. The FDA has noted that it cannot assure the identity, strength, quality, or purity of compounded drug products in the same way it can for approved medications.
Clinical Evidence
All published clinical trial data on semaglutide — including the STEP program trials and STEP UP data — was generated using the FDA-approved branded formulation at specified doses and concentrations. Research suggesting that semaglutide may support weight loss of approximately 14.9% over 68 weeks (STEP 1) or 18.7% over 72 weeks (STEP UP) reflects outcomes with the approved product under controlled trial conditions. Whether compounded formulations produce equivalent outcomes is not established by this evidence base.
Cost
Cost has been the primary driver of patient interest in compounded semaglutide. During the shortage period, compounded programs were frequently available through telehealth platforms at monthly costs of $150 to $350, compared with brand-name list prices exceeding $1,000. This cost differential has remained a significant factor in access to GLP-1-based weight loss programs for individuals without comprehensive insurance coverage.
How Telehealth Platforms Facilitate Access
Telehealth has been the dominant channel through which compounded semaglutide programs have reached patients. Platforms operating in this space typically offer an online intake process, a synchronous or asynchronous consultation with a licensed prescriber, issuance of a patient-specific prescription to a partnered compounding pharmacy, and home delivery of the prescribed medication.
Among the providers operating in this segment, the TrimRx weight loss program has structured its service around physician-supervised GLP-1 treatment with home delivery, offering a model that reflects the broader industry approach to telehealth-enabled weight management. Programs such as this typically include ongoing provider access as part of the monthly fee, which is structured to cover both the medication and the clinical oversight component.
What Individuals Should Consider
The regulatory environment for compounded semaglutide continues to evolve, and the legal landscape may change further depending on FDA policy decisions, litigation outcomes, and congressional activity. Individuals who are currently using or considering compounded semaglutide programs should be aware of the following:
- Compounded semaglutide should only be obtained through a licensed 503A pharmacy with a valid prescription from a licensed US healthcare provider.
- Products marketed as “semaglutide” that are sold without a prescription, or that include salt forms such as semaglutide sodium or acetate (which are not the same molecule as the approved drug), may carry additional safety and legal risks.
- Individuals with contraindications to GLP-1 therapy — including a personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, or a history of pancreatitis — should not use these medications regardless of their source.
- Individuals considering weight loss options involving semaglutide may wish to consult a qualified healthcare provider to review their full medical profile and determine appropriate next steps.
The Cost Equation: Why Compounded Products Found an Audience
To understand why compounded semaglutide became so widespread, the cost differential with branded alternatives is the essential context. Brand-name Wegovy carried a list price exceeding $1,300 per month before insurance in 2023, and commercial insurance coverage for weight management medications was inconsistent across plans. Medicare Part D was prohibited from covering anti-obesity medications for most of the shortage period. In contrast, telehealth platforms offering compounded semaglutide programs marketed monthly costs of $150 to $350, inclusive of medication and consultation — a price point accessible to a substantially larger population of patients without comprehensive coverage.
This cost gap drove adoption among individuals who were clinically eligible for GLP-1 therapy but priced out of the branded market. Researchers estimate that more than 137 million US adults may be eligible for semaglutide based on obesity, diabetes, or cardiovascular risk criteria alone — a population that vastly exceeds current prescription volumes, with cost being among the primary access barriers. Compounded programs, whatever their regulatory limitations, addressed a genuine unmet need in a market where the branded supply chain was both unavailable and unaffordable for many patients.
Navigating Access in the Current Environment
For individuals currently enrolled in or evaluating compounded semaglutide programs, the practical path forward depends on several variables: the specific pharmacy and prescriber involved, the state in which the patient resides, the evolution of FDA policy, and whether brand-name alternatives are covered by their insurance. The telehealth weight loss market was estimated at $6.9 billion in 2023 and continues to grow, with both compounded and branded options available through various platforms at different price points.
Among the providers structuring telehealth weight loss programs in this environment, TrimRx weight loss program has built its model around physician-supervised GLP-1 care with home delivery and licensed provider oversight, beginning at $179 per month. Programs with this kind of integrated structure — combining prescriber access, clinical monitoring, and medication logistics — offer the infrastructure that regulatory-compliant, medically sound GLP-1 treatment requires, regardless of which specific medication the prescribing provider determines is most appropriate for the individual patient.
Conclusion
Compounded semaglutide has provided access to GLP-1-based weight management for a substantial population of US adults who may not have been able to afford brand-name alternatives. The regulatory framework permitting this access was time-limited to the shortage period, and the landscape has shifted considerably since early 2025. For individuals evaluating options, understanding the distinction between FDA-approved medications and compounded alternatives — including their differing regulatory statuses, evidence bases, and evolving legal contexts — is an important part of making an informed decision with the guidance of a qualified healthcare provider.
